Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma

被引:43
作者
Shen, Ying-Chun [1 ,2 ,3 ]
Hsu, Chia-Lang [3 ,4 ]
Jeng, Yung-Ming [5 ]
Ho, Ming-Chih [6 ]
Ho, Cheng-Maw [6 ]
Yeh, Ching-Ping [2 ]
Yeh, Chia-Yu [2 ]
Hsu, Meng-Chi [2 ]
Hu, Ray-Heng [6 ]
Cheng, Ann-Lii [1 ,2 ,3 ]
机构
[1] Natl Taiwan Univ, Canc Ctr, Dept Med Oncol, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Natl Taiwan Univ, Grad Inst Oncol, Sch Med, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan
关键词
Intratumor heterogeneity; Tumor immune microenvironment; Hepatocellular carcinoma; TERTIARY LYMPHOID STRUCTURES; PD-L1; EXPRESSION; INFILTRATING LYMPHOCYTES; PROGNOSTIC VALUE; T-CELLS; HETEROGENEITY; LANDSCAPE; RESECTION; SURVIVAL;
D O I
10.1016/j.jhep.2019.09.032
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Intratumor heterogeneity has frequently been reported in patients with hepatocellular carcinoma (HCC). Thus, the reliability of single-region tumor samples for evaluation of the tumor immune microenvironment is also debatable. We conducted a prospective study to analyze the similarity in tumor immune microenvironments among different regions of a single tumor. Methods: Multi-region sampling was performed on newly resected tumors. The tumor immune microenvironment was evaluated by immunohistochemical staining of PD-L1, CD4, CD8, CD20, FoxP3, DC-LAMP (or LAMP3), CD68, MPO, and tertiary lymphoid structures (TLSs). PD-Ll expression was manually quantified according to the percentage of PD-Ll -stained tumor or stromal cells. The densities (number/mm(2)) of immune cells and the number of TLSs per sample were determined by whole-section counting. RNA-sequencing was applied in selected samples. Similarities in tumor immune microenvironments within each tumor were evaluated by multivariate Mahalanobis distance analyses. Results: Thirteen tumors were collected from 12 patients. The median diameter of tumors was 9 cm (range 3-16 cm). A median of 6 samples (range 3-12) were obtained from each tumor. Nine (69.2%) tumors exhibited uniform expression of PD-Ll in all regions of the tumor. Out of 13 tumors analyzed by immunohistochemical staining, 8 (61.5%) tumors displayed a narrow Mahalanobis distance for all regions within the tumor; while 8 (66.7%) of the 12 tumors analyzed by RNA-sequencing displayed a narrow Mahalanobis distance. Immunohistochemistry and RNA-sequencing had a high concordance rate (83.3%; 10 of 12 tumors) for the evaluation of similarities between tumor immune microenvironments within a tumor. Conclusions: A single-region tumor sample might be reliable for the evaluation of tumor immune microenvironments in approximately 60-70% of patients with HCC. Lay summary: Heterogeneity in the regional immune microenvironments of tumors has been reported in patients with hepatocellular carcinoma. This heterogeneity could be an obstacle when trying to reliably evaluate the immune microenvironment of an entire tumor using only a single-region tumor sample, which may be the only option in patients with more advanced disease. Our study utilized both immunohistochemical and transcriptomic analyses to demonstrate that a single-region sample is reliable for evaluation of tumor immune microenvironments in 60-70% of patients with hepatocellular carcinoma. (C) 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:489 / 497
页数:9
相关论文
共 42 条
[1]   Multiplexed ion beam imaging of human breast tumors [J].
Angelo, Michael ;
Bendall, Sean C. ;
Finck, Rachel ;
Hale, Matthew B. ;
Hitzman, Chuck ;
Borowsky, Alexander D. ;
Levenson, Richard M. ;
Lowe, John B. ;
Liu, Scot D. ;
Zhao, Shuchun ;
Natkunam, Yasodha ;
Nolan, Garry P. .
NATURE MEDICINE, 2014, 20 (04) :436-+
[2]   Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival [J].
Brunner, Stefan M. ;
Itzel, Timo ;
Rubner, Christoph ;
Kesselring, Rebecca ;
Griesshammer, Eva ;
Evert, Matthias ;
Teufel, Andreas ;
Schlitt, Hans J. ;
Fichtner-Feigl, Stefan .
ONCOTARGET, 2017, 8 (41) :71002-71011
[3]   Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma [J].
Calderaro, Julien ;
Petitprez, Florent ;
Becht, Etienne ;
Laurent, Alexis ;
Hirsch, Theo Z. ;
Rousseau, Benoit ;
Luciani, Alain ;
Amaddeo, Giuliana ;
Derman, Jonathan ;
Charpy, Cecile ;
Zucman-Rossi, Jessica ;
Fridman, Wolf Herman ;
Sautes-Fridman, Catherine .
JOURNAL OF HEPATOLOGY, 2019, 70 (01) :58-65
[4]   Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples [J].
Casadevall, David ;
Clave, Sergi ;
Taus, Alvaro ;
Hardy-Werbin, Max ;
Rocha, Pedro ;
Lorenzo, Marta ;
Menendez, Silvia ;
Salido, Marta ;
Albanell, Joan ;
Pijuan, Lara ;
Arriola, Edurne .
CLINICAL LUNG CANCER, 2017, 18 (06) :682-+
[5]   Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma [J].
Dai, Xiaomeng ;
Xue, Jun ;
Hu, Jianli ;
Yang, Sheng-li ;
Chen, George G. ;
Lai, Paul B. S. ;
Yu, Chao ;
Zeng, Cui ;
Fang, Xiefan ;
Pan, Xiaoli ;
Zhang, Tao .
TRANSLATIONAL ONCOLOGY, 2017, 10 (04) :511-517
[6]   Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers [J].
Dieu-Nosjean, Marie-Caroline ;
Giraldo, Nicolas A. ;
Kaplon, Helene ;
Germain, Claire ;
Fridman, Wolf Herman ;
Sautes-Fridman, Catherine .
IMMUNOLOGICAL REVIEWS, 2016, 271 (01) :260-275
[7]   STAR: ultrafast universal RNA-seq aligner [J].
Dobin, Alexander ;
Davis, Carrie A. ;
Schlesinger, Felix ;
Drenkow, Jorg ;
Zaleski, Chris ;
Jha, Sonali ;
Batut, Philippe ;
Chaisson, Mark ;
Gingeras, Thomas R. .
BIOINFORMATICS, 2013, 29 (01) :15-21
[8]   CD86+/CD206+, Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis [J].
Dong, Pingping ;
Ma, Lijie ;
Liu, Longzi ;
Zhao, Guangxi ;
Zhang, Si ;
Dong, Ling ;
Xue, Ruyi ;
Chen, She .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (03)
[9]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[10]   GENCODE reference annotation for the human and mouse genomes [J].
Frankish, Adam ;
Diekhans, Mark ;
Ferreira, Anne-Maud ;
Johnson, Rory ;
Jungreis, Irwin ;
Loveland, Jane ;
Mudge, Jonathan M. ;
Sisu, Cristina ;
Wright, James ;
Armstrong, Joel ;
Barnes, If ;
Berry, Andrew ;
Bignell, Alexandra ;
Sala, Silvia Carbonell ;
Chrast, Jacqueline ;
Cunningham, Fiona ;
Di Domenico, Tomas ;
Donaldson, Sarah ;
Fiddes, Ian T. ;
Giron, Carlos Garcia ;
Gonzalez, Jose Manuel ;
Grego, Tiago ;
Hardy, Matthew ;
Hourlier, Thibaut ;
Hunt, Toby ;
Izuogu, Osagie G. ;
Lagarde, Julien ;
Martin, Fergal J. ;
Martinez, Laura ;
Mohanan, Shamika ;
Muir, Paul ;
Navarro, Fabio C. P. ;
Parker, Anne ;
Pei, Baikang ;
Pozo, Fernando ;
Ruffier, Magali ;
Schmitt, Bianca M. ;
Stapleton, Eloise ;
Suner, Marie-Marthe ;
Sycheva, Irina ;
Uszczynska-Ratajczak, Barbara ;
Xu, Jinuri ;
Yates, Andrew ;
Zerbino, Daniel ;
Zhang, Yan ;
Aken, Bronwen ;
Choudhary, Jyoti S. ;
Gerstein, Mark ;
Guigo, Roderic ;
Hubbard, Tim J. P. .
NUCLEIC ACIDS RESEARCH, 2019, 47 (D1) :D766-D773